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Received 14 October 2008; received in revised form 30 April 2009; accepted 21 May 2009Abstract The expansion of national and international research efforts in stem cell research is increasingly paired with the
trend of establishing stem cell banks and registries. In jurisdictions crossing the spectrum of restrictive to liberal stem cell
policies, banks and registries are emerging as an essential resource for transnational access to quality-controlled and ethically
sourced stem cell lines. In this study, we report the preliminary findings of a survey of stem cell banks participating in the
International Stem Cell Forum's International Stem Cell Banking Initiative (ISCBI). The questionnaire circulated to all ISCBI
members addressed both general issues surrounding research policies (e.g., national policies regulating the permissibility of
conducting embryonic stem cell research (hESCR)) and, more specifically, issues relating to the governance of stem cell banking
projects. The results of the questionnaire were complemented by scholarly research conducted by the authors. This article
provides an overview of the current international hESC banking landscape (I). For this purpose, the policy and governance
approaches adopted in the surveyed stem cell banks at the national level will be analyzed and areas of convergence and
variance will be identified (II). It is beyond the scope of this paper to provide a comprehensive analysis of the wide range of
possible governance approaches, policy responses, and their implications. However, we want to provide a starting point for
discussion surrounding key questions and challenges as concerns provenance, access, and deposit of hESC lines (III). Finally,
while our analysis is focused on research grade hESCs, the lessons to be gleaned from this examination will encourage further
thought, analysis, and research into the issues raised in the banking and governance of other sources of stem cell lines (e.g.,
SCNT, parthenogenesis, iPs) (IV).
© 2009 Elsevier B.V. All rights reserved.Introduction
The expansion of national and international research efforts
in stem cell research is increasingly paired with the trend of
establishing stem cell banks and registries (e.g., UK Stem
Cell Bank, USA-NIH registry, Spanish National Stem Cell Bank,
European hESC registry, UMASS International Stem Cell
Registry, etc.). In jurisdictions crossing the spectrum of
restrictive to liberal stem cell policies (Isasi and Knoppers,⁎ Corresponding author.
E-mail address: rosario.isasi@umontreal.ca (R.M. Isasi).
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doi:10.1016/j.scr.2009.05.0032006a), banks and registries are emerging as an essential
resource for transnational access to quality-controlled and
ethically sourced stem cell lines from different origins (e.g.,
embryonic, adult, SCNT) and grades (e.g., research,
clinical).
Both stem cell banks and registries have distinct and
complementary scientific value. Whereas stem cell banks
represent a collection of biological materials (i.e., stem cell
lines of embryonic and/or adult origin) and the associated
data stored within an organized system (OECD, 2006) (e.g.,
UK Stem Cell Bank, Spanish Stem Cell Bank), registries
consist of databases or catalogs documenting the scientific
and ethical provenance of the stem cell lines (e.g., European
Human Embryonic Stem Cell Registry). It is important to.
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number of different levels and types of operations as well as
institutions (Stacey, 2007). Stem cell banks range from public
(e.g., UK Stem Cell Bank, Spanish National Stem Cell Bank) to
institutional (Tel Aviv Sourasky Medical Center Cell Bank) and
commercial banks (e.g., WiCell International Stem Cell
Bank), or to local laboratories (e.g., Stem Cell Research
Center, Kyoto University; France Biomedicine Agency,
National Registry of hESC). Moreover, the term could also
refer to a centralized institute that provides cell stocks for
research (US National Stem Cell Bank, Singapore Stem Cell
Bank), a national supply centre, or a repository of hES cells
for a broad range of researchers (e.g., Indian National Centre
for Stem Cell Science,). Finally, the term “stem cell bank”
could also refer to an international stem cell registry (e.g.,
UMass International Stem Cell Registry, European hESC
Registry). Here, we will use the term “bank” to encompass
all of the wide ranges of institutions referred to above.
In order to maintain internal consistency with policy
frameworks relating to the permissibility of conducting stem
cell research, stem cell banks and registries aim to avoid
redundancy in research projects and to eliminate the need
for the derivation of additional stem cell lines. The latter is
of particular relevance to cell lines of embryonic origin given
the surrounding political and moral controversies. Illustra-
tive of this is the stated mandate of the United Kingdom's
Stem Cell Bank “to reduce the need for individual research
teams to generate their own stem cell lines and in turn to
reduce the use of human tissues and embryos” (UK Stem Cell
Bank, 2007). Likewise, the core mandate of the European
Human Embryonic Stem Cell Registry (hESCReg) aims for the
“responsible limitation of the number of embryos needed for
derivation of new cell lines…” (European Commission, 2008).
In this study, we report the preliminary findings of a
survey of stem cell banks participating in the International
Stem Cell Forum's International Stem Cell Banking Initiative
(ISCBI) (Table 1). The questionnaire circulated to all ISCBI
members addressed both the general issues surrounding
research policies (e.g., national policies regulating theTable 1 ISCBI registry of national banks/registries of stem cell li
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Taiwan • Taiwan Stem Cell Banpermissibility of conducting embryonic stem cell research
(hESCR)) and, more specifically, the issues relating to the
governance of stem cell banking projects. The results of the
questionnaire were complemented by scholarly research
conducted by the authors.
This article provides an overview of the current
international hESC banking landscape (I). For this purpose,
the policy and governance approaches adopted in the
surveyed stem cell banks at the national level will be
analyzed and areas of convergence and variance will be
identified(II). It is beyond the scope of this paper to
provide a comprehensive analysis of the wide range of
possible governance approaches, policy responses, and
their implications. However, we want to provide a starting
point for discussion surrounding key questions and chal-
lenges as concerns provenance, access, and deposit of hESC
lines (III). Finally, while our analysis is focused on research
grade hESCs, the lessons to be gleaned from this examina-
tion will encourage further thought, analysis, and research
into the issues raised in the banking and governance of
other sources of stem cell lines (e.g., SCNT, parthenogen-
esis, iPs) (IV).I. International stem cell banking initiatives: Toward
harmonization and standardization
The emergence of national stem cell banks is accompanied
by the establishment of international initiatives addressing
harmonization and standardization processes for stem cell
research and banking. These initiatives share the vision of
stem cell research as a global enterprise. They are as
follows: the International Stem Cell Banking Initiative
(ISCBI) by the International Stem Cell Forum, the European
Commission's Human Embryonic Stem Cell Registry
(hESCReg), UMASS International Stem Cell Registry, and
finally, the “Registry of Human Embryonic Stem Cell Lines
Provenance” by the International Society for Stem Cell
Research (ISSCR).nes
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98 R.M. Isasi, B.M. KnoppersThe above-noted initiatives also share a common goal: the
promotion of international collaboration for the timely
realization of the scientific promise offered by stem cell
research. Thus, they seek policy harmonization along with
the standardization of technical standards and safety
requirements. They further aim to provide guidance on
how to navigate the “policy patchwork” that characterizes
the current state of stem cell research.
A description of the international initiatives mentioned
requires the clarification of terminology. There is confusion in
both the general and the scientific literature1 regarding the
concepts of harmonization and standardization (or unifica-
tion). We have described elsewhere the nature and scope of
these two very distinctive processes and terms (Isasi, 2009).
The term “harmonization” refers to the process in which
diverse elements are combined or adapted to each other so as
to form a coherent whole, while retaining their individuality
(Boodman, 1991). Harmonization is thus a process of
recognizing and reconciling differences, which presupposes
and preserves the diversity of the objects to be harmonized.
In the context of stem cell research, we see policy
harmonization in the adoption of a framework of funda-
mental ethical and governance principles (Isasi and Knoppers,
2006b) (i.e., respect for autonomy, privacy, and confidenti-
ality; ethics review; oversight; etc.) regulating the deriva-
tion, use, and banking of hESC lines, albeit with different
cultural and local interpretations. Thus, harmonization
should be identified with policy convergence as opposed to
standardization or unification. In contrast, the term “stan-
dardization” refers to the processes of scientific guidance in
the adoption of uniform scientific and technical requirements
and common guidelines (International Conference on Harmo-
nisation website). Furthermore, the standardization of
policies or practices seeks the adoption of uniform model
codes, guidelines, or treaties. Consequently, in this article our
argument for the adoption of a global governance framework
for stem cell banking is a call for policy convergence.
The International Stem Cell Banking Initiative
Despite the proliferation of stem cell banks around the
world, a critical discussion about appropriate mechanisms
for both domestic and international banking and governance
has yet to take central stage. Of particular importance is the
challenge of transnational collaboration given the hetero-
geneity of ethical and legal frameworks affecting the
permissibility of conducting stem cell research in all stages,
from derivation and use, to banking and distribution.
To address this gap, in 2007 the International Stem Cell
Forum launched the International Stem Cell Banking Initiative,
with the goal of establishing a set of international minimum
standards—or best practice guidelines—for banking, character-
ization, and testing. It is also the aim of ISCBI to create a solid
ethical framework for international cell banking and research.1 For instance, see the following statement: “although we should
not expect harmonization of international laws with respect to stem
cell research, we should strive to develop international consensus
on ethical and scientific standards and practice…” Matthews, D.J.,
Donovan, P., Harris J., et al. 2006. Integrity in International Stem
Cell Research Collaborations. Science 313, 921-392.The International Stem Cell Banking Initiative aims to
promote, among other things, minimum standards for cell line
quality control and comparability of data produced in different
centres around the world. An additional objective is to
facilitate the international exchange of cell lines and other
research materials. Furthermore, it is the goal of ISCBI to
create a global network of stemcell banks by providing support
to existing banks and encouraging the development of new
banks inmember countries. To achieve this objective, the ISCBI
has established a Registry of National Banks of Stem Cell Lines.
A key output of the ISCBI has been the adoption of a
“Consensus Guidance for Banking and Supply of Human
Embryonic Stem Cell Lines for Research Purposes” (ISCF;
International Stem Cell Banking Initiative, 2008), which seeks
to standardize and establish best practice for the banking,
testing, and distribution of hES cells for research purposes. The
guidance covers awide range of processes involved in stemcell
banking (e.g., procurement of cell lines, cell banking
procedures and documentation, cell banking quality control,
and process of releasing cell banks) and establishes technical
requirements (e.g., release criteria, microbiological testing,
cell characterisation. and shipment of cells). It also addresses
core ethical issues (e.g., informed consent, oversight, and
licensing; traceability and documentation of cell provenance).European Human Embryonic Stem Cell Registry
Another important harmonization and standardization effort
that highlights the significance of international cooperation
is the European Commission's initiative in the creation of a
Human Embryonic Stem Cell Registry. The recently launched
European Embryonic Stem Cell Registry was founded within
the 6th Framework Programme for Research and Technolo-
gical Development of the European Commission (European
Parliament, 2002; European Commission, 2006). The
hESCReg aims to systematically and comprehensively catalog
cell derivation and cultivation methods, gene and protein
expression profiles, and available biological data in vitro and
in vivo. It will also examine legal documentation from hESC
lines obtained from ongoing and future European Commis-
sion-funded research projects.
Following European policy, the registry will not accept
stem cell lines that have been created through research that
implicates any of the nonfundable activities (European
Parliament, 2006) (European Council, 2006), nor will it
accept proposals for use of registry cells for any such
research. Since research activities destroying human
embryos are not eligible for EU funding, stem cells procured
through these prohibited research activities are not eligible
to be registered. However, it is important to note that
research using stem cells derived from surplus human
embryos may be eligible for EU funding following the ethical
approval required for all EU-funded research (European
Embryonic Stem Cell Registry website).
The European hESCReg was created to foster transnational
networking between banks and researchers worldwide. It
provides both an internet portal to facilitate research projects
and ongoing access to comprehensive information about
human embryonic stem cell lines. Given the variety of policy
approaches regarding stem cell research in Europe, the
hESCReg can be seen as a pilot project aiming to solve the
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arising from transnational collaboration in the field.
UMASS International Stem Cell Registry
Launched in 2008, the International Stem Cell Registry at
UMASS was funded by the Massachusetts Life Science Center,
with the mission of “providing a searchable, comprehensive
database that includes published and validated unpublished
information on all of hESC and other pluripotent cell lines
(e.g., iPS) (UMASS International Stem Cell Registry website).
The registry seeks to be comprehensive in scope and so will
accept stem cell lines derived by or deposited in national and
international stem cell banks, industry, academic centers,
and nonprofit institutions. Furthermore, information about
the provenance of the lines is also collected by the registry as
well as scientific literature relating to the stem cell lines
(Luong et al., 2008). If successful, the registry will provide a
major contribution to the field, as it has been designed to be
a one-stop shop repository of comprehensive, public, and
current information regarding pluripotent stem cell lines
worldwide.
International Society for Stem Cell Research
(ISSCR)—“Registry of Human Embryonic Stem
Cell Lines Provenance”
The International Society for Stem Cell Research is another
initiative to foster global governance and facilitate interna-
tional cooperation in stem cell research and banking. ISSCR
seeks the harmonization of core ethical principles through
the adoption of the “Guidelines for the Conduct of Human
Embryonic Stem Cell Research” (ISSCR, 2006). The guidelines
seek to promote responsible, transparent, and uniform
practices worldwide.
In the specific context of stem cell banking, the ISSCR's
guidelines encourage the establishment of national and
international repositories to facilitate the exchange and
dissemination of stem cell lines. They also call for the
adoption of standardized methods and practices. Further-
more, the guidelines propose the creation of a “Registry of
Human Embryonic Stem Cell Lines Provenance.” The pro-
posed registry, which will be developed, maintained, and
curated by ISSCR, consists of the creation of an online
database providing independent validation of the prove-
nance of human embryonic stem cell lines. The registry is
still under development and no information has been
disclosed regarding its governance structures and operating
procedures for documentation and evaluation, among other
important issues. Consequently, questions remain as to how
ISSCR will deal with issues such as quality control, validation,
accountability, and liability given its lofty goal of providing a
certificate of “validation” vouching for the ethical and legal
provenance of the registered stem cell lines.
II. National approaches to hESC banking
As noted in the Introduction, the present study aims to
provide an overview of the current hES cell banking
landscape (see Table 1). The analysis that follows is basedon a review of the 18 institutions (13 jurisdictions) that
participated in the ISCBI survey. The information collected
was obtained by direct responses to the survey and
complemented by information available in public sources.
It should be noted that the majority of these banking
initiatives are still under development. It should also be
noted that as the field is rapidly evolving our findings reflect
the state of activities as of March 2009.
In the spirit of international and public transparency one
could presume that the governance structures and processes
adopted by stem cell banks and registries would be made
available for evaluation and quality control by anyone
seeking to use or study them. However, this was not the
case for a number of stem cell banks and registries. The lack
of disclosure of information is an ethical issue in itself that
deserves further analysis in the future.
The first convergent point in the banks under study relates
to their objectives: they all aim to avoid redundancy in
research projects and to eliminate the need for derivation of
additional stem cell lines (e.g., UK, Canada, and Spain). A
second point is that the banks largely aim to guarantee the
quality, availability, and ethical provenance of the hESC lines
they curate (e.g., UMASS, European hECReg). With respect to
their role in quality and safety assurance, their mandate
includes the characterization, culture, andmaintenance of the
cell lines. Additionally, theprovision of technical support to the
research community constitutes oneof their coreobjectives. In
summary, such stem cell banks have been created with the
lofty goal of being the stewards of the scientific (and ethical)
integrity of the stem cell lines they acquire, store, and
distribute (e.g., UK, India, Singapore, Korea, Spain).
Nevertheless, divergence is also present in the approaches
that countries and jurisdictions have taken to create and
govern stemcell banks and registries. Some stemcell banks and
registries have been statutorily created (e.g., legislation or
executive orders), their mandate and governance structure
established through specific legislation (e.g., Spanish National
Stem Cell Bank, UMASS). In some cases, the enabling act that
created and empowered the bank is primary interpreted by the
institution itself (Huhn, 2002). The Spanish National Cell Bank is
a clear example of this public ordering approach, as the bank's
mandate and structure is confined to the enabling legislation
(Spain, 2007). Others are regulated by the rules governing
biobanks generally (e.g., Japan, Korea, and Singapore). Finally,
some banks and registries have opted for a private ordering
approach through self-regulation in their creation and govern-
ance structure, and so they lack a legally binding structure
(e.g., UK Stem Cell Bank, Singapore, and Israel).
All current banking initiatives foresee, like the immortal
cell lines they curate, a long-term existence. In fact, in most
cases a platform is created for prospective banking,
research, and clinical applications, and for collection,
storage, and research uses on an ongoing basis (UK, WiCell,
UMASS, European hESCReg, and Spain). Notwithstanding,
provisions pertaining to the eventual closure or transfer of
assets of the institution, including measures relating to the
consequent disposition of the stored samples and data, are
sorely lacking in most of the cases under study. Similarly
lacking are provisions relating to liability issues. This vacuum
has the potential concomitant effect of weakening proce-
dures intended to provide the institution with an accoun-
table and transparent governance framework.
100 R.M. Isasi, B.M. KnoppersIII. Provenance, access, and deposit of hESC lines
Reflecting the national policy frameworks governing the
permissibility of conducting stem cell research in their
respective jurisdictions, stem cell banks have adopted
different criteria with regard to the cell lines that can be
deposited in their facilities. For instance, in both the British
and the Spanish national banks, cell lines of both embryonic
and adult origin are to be deposited. Whereas in the United
States, deposit in the National Stem Cell Bank is restricted to
only those hESC lines that are eligible for federal funding.
Likewise, the French registry accepts for deposit hESC lines
derived or used in the country.
In many cases, licensing and funding requirements legally
bind researchers to deposit any resultant stem cell lines (and
accompanying data) in the bank or the registry (e.g., Spain,
UK, EuropeanhESCReg, France, Japan, and India). Thepurpose
of this requirement is twofold: first, to ensure tight regulation
and appropriate governance, and second, to ensure effective
pooling of resources among the scientific community (e.g.,
France, Japan, Singapore, Thailand, Korea, Czech Republic,
Australia (to be established) and Canada (to be established)).
Moreover, the mechanisms for deposit and access vary
greatly across the banks. In the UK, for instance, applications
for deposit and access (UK Stem Cell Bank, 2007) to the stem
cell lines are subject to approval on a case-by-case basis by a
nonstatutory body, the Steering Committee for the UK Stem
Cell Bank and for the Use of Stem Cell Lines. The criteria
adopted by the Steering Committee reflect the principles
adopted in HFEA's policy. It states that the lines “have been
ethically sourced, with fully informed donor consent, and that
the cell lines present a valuable resource for the biomedical
research community” (UK Stem Cell Bank, 2007). Overall, the
Steering Committee ensures that cell lines are used only by
bona fide research groups for justifiable and valuable purposes
that reflect the requirements of the HFEA regulations.
As is the case of other national stemcell banking initiatives,
the UKSCB receives cell lines from elsewhere but mandates
deposit by its licensing authority. The UKSCB is the regulator-
mandated repository for all embryonic stem cell lines derived
in the UK. The Human Fertilisation and Embryology Authority
(HFEA) requires as a condition for the licensing of newly
derived hESC lines that a sample line be deposited in the UK
Stem Cell Bank. Likewise, in Spain and France it is statutorily
mandated that all stemcell lines createdwith either private or
public funds in the countrymust be deposited in the respective
national banks. Similarly, in the United States all pluripotent
cell lines derived using federal funds (NIH, 2007) must be
deposited in its National Stem Cell Bank.
In Spain, access to stem cell lines deposited in the bank
is on a case-by-case basis and is subject to a license by the
Commission of Guarantees for the Donation and Use of
Cells and Human Tissues, and by the Autonomous Commu-
nity Authority. Requests for access must follow the ethical,
legal, and technical requirements established in the law
and the bank's regulations (e.g., informed consent, ethics
review and approval, and the prohibition of financial gain
for the donation of reproductive materials) (Spain, 2006,
2007).
Policy convergence across national stem cell banks is
present in the adoption of fundamental ethical principles and
research governance requirements across jurisdictions.Specifically, policy convergence is amenable to core ethical
principles such as respect of autonomy (e.g., informed
consent), respect for privacy and confidentiality (e.g.,
protection for donor identity given the potential for trace-
ability in hESC lines), and noncommercialization of human
reproductive materials (translated in restrictions on mone-
tary compensation for gamete and tissue donation). However,
a number of initiatives have no information available with
respect to the measures implemented to protect the privacy
and confidentiality of donors of reproductive materials (e.g.,
India, Israel, France, Spain, Japan, Korea, etc.).
Furthermore, in terms of research governance provisions,
convergence is also present in the adoption of internal
mechanisms for the scientific and ethics review of: (a) the
procurement of gametes, embryos, and other cells from
human donors for the generation of stem cell lines; and (b)
the research and use of already derived hESC lines.
The requirement of demonstrating ethical and scientific
provenance of the cell line as a condition of license is the one
procedural mechanism with the greatest impact on stem cell
research. Such an oversight mechanism, with its traditional
requirements of certification, quality assurance, standard
operating procedures, reporting procedures, and ethics
approval, can effectively frame and even curtail access
and thus influence the conduct of research itself. None-
theless, very little has been said with respect to the type of
ethical review and ongoing oversight that is required for
long-term infrastructures like stem cell banks and registries.
In terms of ethical and scientific assessment, across the
board, all banks require proof of prior local ethical and scientific
review and approval, as well as compliance with licensing re-
quirements by the appropriate local entities (e.g., Israel, Japan,
UK, Spain, India, UMass, European hESCReg, and WiCell).
However, the majority of banks under study have yet to
establish transparent and consistent criteria for the accessing
and depositing of stem cell lines derived in a foreign jurisdiction
(e.g., HarvardUniversity StemCell Collection, Japan, India, and
Korea).
Likewise, provisions to assess review processes or to verify
transnational practices and standards, in order to vouch for
the ethical, scientific, and legal provenance of a stem cell
line of foreign origin, are only emerging. Given the interna-
tional realities of stem cell research, this significant gap in
existing regulatory frameworks has the potential to consti-
tute a serious roadblock for seamless international collabora-
tion, and ultimately, for the fulfillment of the goals of a stem
cell banking initiative in itself. Accordingly, initiatives like
the one proposed by ISSCR with the creation of a registry
validating the provenance of hESC lines, and the already
created European hESCReg andUmass International StemCell
Registry, have important roles to play in order to fill this
vacuum.
In terms of the transnational sharing of stem cell lines in
general, three emerging policy options have been proposed or
implemented in various jurisdictions (Lomax and McNab, 2008;
Isasi, 2009) (Table 2). They consist of policies (a) mandating
absolute ethical and legal equivalency (e.g., Czech Republic) or
(b) establishing reciprocal policy agreements in order to grant
(presumed) ethical provenance of the cell lines (California
CIRM, Canada CIHR, andUK SCB). Finally, a common approach is
to resort to the use of broad (and sometimes vague)
“substantially equivalency” or “acceptably derived” criteria
Table 2 Cross-jurisdictional transfer of hESC lines: Policy approaches a
Policy approach Advantages Disadvantages and challenges
“Absolute Ethical and Legal Equivalency”
Criterion:
• Mechanisms for assessment and review
of practices are clear.
• Confuses policy convergence with
unification or standardization.
• Requires absolute ethical and legal
equivalency across national policies.
• Ignores sovereignty and moral diversity
• Local laws and regulations are the only
acceptable model.
• Unfeasible and excessively stringent
• Restricts availability of hESC lines (e.g.,
grandfathering clauses not allowed)
“Substantially Equivalent” Criterion: • Policy convergence toward core socio-
ethical concerns and fundamental
ethical principles.
• Potential challenges are to maintain
internal consistency when judging the
substantial equivalency of policies and
to avoid arbitrary applications.
• Derivation, research, and banking are
permissible provided that the
jurisdictions adopt substantially
equivalent ethical and legal
requirements.




“Reciprocal Policy Agreements” Criterion: • Harmonization effort aimed at avoiding
patchworks within jurisdictions by
consistently requiring compliance with
set ethical and other requirements.
• Dangers of internal inconsistencies with
respect to national policies.
• Transnational transfer of cells accepted
if hESC lines have been derived by,
deposited in, or approved for use by a
licensed entity formally recognized as
having adopted consistent ethical and
legal standards.
• Facilitates research cooperation while
respecting divergence in national policy
approaches.
• Efficient and transparent approach.
a Excerpts from: Isasi, R.M., April 2009. Policy interoperability in stem cell research: demystifying harmonization. Stem Cell Rev and Rep
(2009) 5:108–115.
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with different degrees—pose challenges in terms of assessing
variations in the regulation of core ethical requirements across
jurisdictions. A further challenge they pose is the maintenance
of internal consistency and transparency with regard to their
policy frameworks governing stem cell research in general. For
instance, how to determine which variations should be deemed
as significant enough as to erode the core ethical principles and
moral values enshrined in a given jurisdiction? How to evaluate
the context in which derivation, research, and distribution take
place? On the other hand, a major advantage of the latter two
approaches is that they provide prospective strategies toward
streamlining review processes and the verification of cross-
jurisdictional practices and standards.
The transnational sharing of stemcellmaterials and related
data are largely dependent on the ability of stem cell banks to
harmonize in many crucial areas—not least with regard to
normative and ethical principles, oversight, governance
mechanisms, technical and security standards, quality assur-2 The British NSCB, for instance, accepts stem cell lines where
ethical sourcing can be presumed, as it is the case for stem cell lines
that are registered in the United States National Institute of
Health's Pluripotent Stem Cell Registry. It is the mandate of the
UKSCB Steering Committee to establish the criteria for ethical
provenance.ance, and scientific practices. The absence of provisions
addressing the cross-jurisdictional sharing of hESC lines could
thwart the advancement of research by potentially limiting
some transactions, narrowing then the availability of hESC
lines, and consequentially impacting the quality and nature of
the research. Accordingly, the adoption of interoperable
quality assurance standards and clear consents to interna-
tional access and exchange are essential.
A flexible and proactive global integration strategy is also
imperative for the viability of a stem cell bank. Current
heterogeneous socio-ethical andpolicy frameworks, alongwith
contentious domestic socio-political contexts, pose a great
challenge for international cooperation. While domestic and
scientific goals are necessarily culturally determined, safety
through quality assurance andongoing research that honors the
consent of donors can only be achieved through ensuring some
level of interoperability via governance structures.
IV. Governance structures
Governance has been generally defined as “the exercise of
authority within a given sphere. It has often been employed
as a synonym for the efficient management of a broad range
of organizations and activities” (Hewitt, 2002). The sustain-
ability of stem cell banks and registries depends on the
implementation of governance mechanisms that ensure their
scientific and ethical integrity. In order to achieve this, their
governance structure, processes, and bodies must be
Table 3 Similarities and differences in the dealing with governance issues
Convergence Divergence and gaps
Policy approaches Internally consistent with general policy
frameworks relating to the permissibility of
conducting stem cell research.
Mixture of public and private ordering
(i.e., statutorily created or self-regulated).
Funding sources Public funding Funding sources and their governance differ.
They seldom influence the institution's
independence, transparency, and accountability.
Mandate and
objectives
Often well-defined and coordinated objectives:
Main goal is the centralization of quality
controlled and ethically sourced hSCL.
Lack of proactive international strategy.
However, some institutions adopt a prospective




The majority of the institutions accept hSCL
of different origins (embryonic, adult) and
grades (research and clinical grade).
Some institutions have adopted strict criteria
to further limit the kind of hSCL they can receive






Case-by-case approval by the institution's
oversight body.
Need proof of prior local ethical and scientific
review and approval.
To ensure tight regulation and effective pooling
of resources among the scientific community, in
many cases licensing and funding requirements
legally bind researchers to deposit hSCL.
Lack of comprehensive and transparent
provisions for the transnational transfer of hSCL.





Tend to promote the availability of hSCL and
data to the widest audience.
Lack of clear and harmonized guidelines for the
scientific and ethical assessment of hSCL
derived outside the jurisdiction.
Governance
structures
Most institutions adopt a centralized and
multilayered structure.
Recognition of the need for adequate scientific
and ethical oversight
All initiatives are of long-term existence:
A platform has been created for prospective
banking, research and clinical applications,
anticipating collection, storage, and research
uses on an ongoing basis.
Some governance structures are complex and
inflexible and present deficiencies in terms of
accountability, transparency, and independence.
Lack of clear provisions pertaining to:
• Ongoing oversight and enforcement mechanisms.
• Closure or transfer of assets, including measures
relating to the consequent disposition of stored
samples and data.
• The avoidance of systemic conflicts of interest.
For instance, there is a lack of separation between
the organization funding and managing the
initiative, as well as in terms of their research and
banking platforms.
Governance bodies Range in their nature: advisory-consultative
to executive-statutory.
Degrees of independence and accountability of
governance bodies vary across the institutions.
Mostly multilayered and collegiate bodies
with limited multidisciplinary membership.
Multidisciplinary membership not always adopted;
favouritism toward “professional expertise.”
Lack of representation of all stakeholders
problematic in terms of maintaining legitimacy.
102 R.M. Isasi, B.M. Knoppersindependent, accountable, and transparent (Cambon-Thom-
sen et al., 2007).
Good governance should be understood at all levels, from
the original institutional design to institutional perfor-
mance. In addition, governance mechanisms act at twolevels: at the internal level through mechanisms governing
the day-to-day activities of the bank, and at the external
level, by independently assessing the overall bank perfor-
mance and making the bank accountable to all its
stakeholders.
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national stem cell banks and registries vary, they all accord
importance to the centralization of quality-controlled and
ethically sourced stem cell lines. Likewise, themajority share
concerns over governance mechanisms that promote trans-
parency, stewardship, and accountability, as well as generate
public support. The process chosen to create, govern, and
evaluate the scientific and ethical integrity of the initiative
(being the bank or the registry) must also ensure the
legitimacy of its “raison d'être” (Deschenes and Salle, 2005).
The UK National Stem Cell Bank thanks to its visionary
design is the first to have an infrastructure ready to receive,
store, and supply stem cell lines from a variety of
technologies (e.g., reprogramming, somatic cell nuclear
transfer) and for distinctive purposes (e.g., research and
clinical applications) (UK Stem Cell Bank, 2007). The UKSCB
governance structure is perhaps the most comprehensive of
all existing stem cell banks. Similarly, the Spanish National
Stem Cell Bank, the USA National Stem Cell Bank, and the
European hESCReg, among others, present clear governance
structures. However, the latter is not the case for all the
banks under study. In some cases, their governance struc-
tures and bodies are not publicly disclosed, and thus, it is
difficult to determine their level of transparency and
independence (e.g., Harvard University Human Embryonic
Stem Cell Collection, India, Japan, Korea, and Singapore).
It could be argued that the governance structures
established for stem cell banks should adopt a prospective
approach. Establishing a flexible and organic infrastructure
mindful of future needs and international norms could
accommodate the rapidly evolving nature of the stem cell
research field. The design of some stem cell banks as noted
above (e.g., UK, UMass, Singapore) reflects this need. Since
their inception they have been conceived as repositories of
stem cell lines of different origins (e.g., somatic and
embryonic), grades (research and clinical), and sources
(local or transnational). Conversely, other initiatives (e.g.,
Spain)—for political reasons—have opted for a rigid approach
by limiting the breadth of lines they curate, thus not taking
into account the rapidly evolving nature of scientific
developments. To accommodate the latter, the creation of
additional infrastructures and governance frameworks would
be needed.
Common to the majority of institutions under study is
public funding (e.g., UK, Spain, USA NSCB, France, European
hESCReg, UMass, and Singapore). However, it is not clear from
the information available what influence—if any—the funding
sources and their mechanisms of distribution play in terms of
the institution's independence, transparency, and account-
ability. Good governance practice calls for a separation
between the organization funding and managing the initia-
tive, from that conducting the review and ongoing oversight.
Multilayered governance configurations are necessary to
promote independence, objectivity, and transparency.
Likewise, it is not clear if in all the institutions studied,
their governance bodies (especially those in charge of
granting licenses for access to, and deposit of, stem cell
lines) are independent from their internal governance
structures or from the management of the institution. This
independence provides a needed additional system of checks
and balances as well as accountability (e.g., Spain).
Furthermore, the separation between governance bodies isdesirable in order to safeguard the interests of the banks'
wide range of stakeholders and to ensure good ethical
practice. Independence is necessary to avoid the risk of these
institutions ending up as being self-serving or being
perceived as such.
Similarly, not all institutions maintain independence
between the banking and the research platforms (e.g.,
Spain, Singapore). Such a separation is much needed in order
to maintain a balance between public interests and that of
third parties, including the research community, as well as to
avoid systemic conflicts of interest. The only exception to
this is the UKSCB, as its Code of Conduct explicitly preempts
the bank from conducting research that might be seen to
produce a conflict of interest between its core mandates,
the distribution of quality stem cell lines and the free
dissemination of accompanying information.
Governance bodies adopted in the banks under considera-
tion range in their nature: from advisory-consultative to
executive-statutory. Similarly across the board, the powers,
roles, and responsibilities of governance bodies tend to vary
quite markedly. Mechanisms for oversight and accountability
have been integrated in different ways, some of them within
the same structure of the organization (e.g., UK), while
others imposed through legislation (e.g., Spain) or the result
of a contract or licensing agreement (e.g., USA NSCB,
European hESCReg).
Transparency on the powers and the composition of
oversight bodies is a sine qua non requirement for sound
governance. However, in most of the institutions under study,
there is lack of transparency in terms of which of the
governance bodies—if any—has the authority to impose
sanctions for violation of policies and legal norms, or for
the ongoing oversight of specific research projects once the
stem cell lines have been released to external users.
Additionally, with regard to the composition of these
governance bodies, of key importance is the issue of
multidisciplinary membership in order to reflect the multi-
plicity of interests at stake, and hence to maintain
legitimacy. It is not apparent whether in the institutions
under study membership is restricted to professionals or
experts, leaving aside, for example, the lay public as it is the
case with the Spanish National Stem Cell Bank, the European
hESCReg, and the US National Stem Cell Bank.Conclusion
Certain issues and challenges dominate the stem cell banking
landscape explored here. While it is recognized that “stem
cell research is a global enterprise that begins at the local
level” (O'Rourke et al., 2008), the majority of current and
emerging national stem cell banking initiatives are not
adopting a global and prospective strategy. What is of
heightened concern is the fact that despite these platforms
being built with the goal of maximizing the reproducibility,
comparability, and transparency of the field (European
Group of Ethics in Science and New Technology, 2007), they
often lack a comprehensive and transparent ethical and
governance framework (Table 3).
In this study, we have identified central issues, conver-
gence points, and gaps in the adoption of such framework, as
well as demonstrated the increasing need for the adoption of
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and scientific guidance.
Yet, several international initiatives seeking harmoniza-
tion of policies and standardization of scientific practices
are emerging (e.g., ISSCR, ISCF, UMass). They all seek global
leadership so as to complement the role of national stem
cell banks. What is more, giving the proliferation of
national banks, these international initiatives aim to
achieve the very important goal of interconnecting national
efforts in order to facilitate international collaboration.
Whether these transnational attempts will succeed, or
whether a global governance framework will emerge from
them, remains to be seen.
A major challenge arising is that the proliferation of both
national and international stem cell banks is creating a
complex patchwork, with institutions competing and dupli-
cating objectives and mandates. The latter is further
complicated by disjointed plans for collaboration between
institutions. As it becomes evident, these shortcomings are
not only creating inefficiencies in terms of the use of
resources and the facilitation of access but most importantly,
they are defeating the original objective that supported the
creation of these institutions in the first place. All of these
banks were created with the shared objectives of fostering
and streamlining international collaboration and the sharing
of data and materials, avoiding redundancy in research
projects and eliminating the need for the derivation of
additional stem cell lines. To achieve maximal effectiveness
what is needed is a global approach that builds collaboration
among all institutions (Luong et al., 2008).
Most important are the issues of legitimacy and transpar-
ency. Public trust is essential for the feasibility of any
scientific endeavor but even more so in an area that has
elucidated so much political, social, and ethical controversy,
that of embryonic stem cell research. The maintenance of
public support is of paramount importance to ensure the
legitimacy of the banks. Trust is in great part influenced by
the effectiveness of the institution's governance structure,
the strength of monitoring, and of scientific and ethical
oversight and by the mechanisms ensuring transparency,
independence, and accountability. It is thus problematic that
—at least for those initiatives already in operation—there is
not public disclosure of their governance structures and their
procedures for sourcing and validation (both scientific and
ethical) of the hESC lines they curate.
Finally, while beyond the scope of the present study, it
should be noted that the majority of the institutions
reviewed, despite being publicly funded initiatives, have
yet to address the challenges posed by social justice issues
related to equitable beneficence (Faden et al., 2003) in
terms of access to research and eventual therapies. Indeed,
the creation of stem cell banks raises fundamental issues of
distributive justice and reciprocity for participating indivi-
duals and populations that must be taken seriously.
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